Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Syndax Pharmaceuticals, Inc. (SNDX)

19.69 +0.04 (+0.20%)
As of 2:57:50 PM EDT. Market Open.
Trade SNDX on Coinbase
Chart Range Bar
Loading chart for SNDX
  • Previous Close 19.65
  • Open 19.69
  • Bid 14.30 x 200
  • Ask 19.36 x 100
  • Day's Range 19.17 - 19.87
  • 52 Week Range 12.99 - 25.59
  • Volume 787,699
  • Avg. Volume 1,805,804
  • Market Cap (intraday) 1.745B
  • Beta (5Y Monthly) 0.37
  • PE Ratio (TTM) --
  • EPS (TTM) -2.51
  • Earnings Date (est.) Nov 2, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 37.55

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

syndax.com

298

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SNDX
6.28%
S&P 500 (^GSPC)
11.89%

1-Year Return

SNDX
21.24%
S&P 500 (^GSPC)
18.44%

3-Year Return

SNDX
9.45%
S&P 500 (^GSPC)
75.02%

5-Year Return

SNDX
17.13%
S&P 500 (^GSPC)
70.73%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 72.79M
Earnings -49.36M
Profit Margin -67.82%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-50M
0
50M
-120.0%
-100.0%
-80.0%

Analyst Insights

View More

Analyst Price Targets

26.00
37.55 Average
19.69 Current
57.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/21/2026
Analyst UBS
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 37 -> 33

Statistics

View More

Valuation Measures

Annual
As of 8/21/2026
  • Market Cap

    1.75B

  • Enterprise Value

    1.79B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.84

  • Price/Book (mrq)

    116.21

  • Enterprise Value/Revenue

    7.10

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -87.52%

  • Return on Assets (ttm)

    -18.67%

  • Return on Equity (ttm)

    -255.93%

  • Revenue (ttm)

    252.25M

  • Net Income Avi to Common (ttm)

    -220.76M

  • Diluted EPS (ttm)

    -2.51

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    554.27M

  • Total Debt/Equity (mrq)

    3,903.45%

  • Levered Free Cash Flow (ttm)

    -150.08M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

19.69 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: